Butein combined with radiotherapy enhances radioresponse of gastric cancer cell by impairing DNA damage repair.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
17 09 2021
Historique:
received: 15 06 2021
accepted: 07 07 2021
pubmed: 17 7 2021
medline: 18 11 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

Radiation therapy is common in the current procedures of cancer treatment, but in many cases, radiation resistance of cancerous tissue limits efficacy in clinical applications. Therefore, the use of radiosensitizers has been introduced as an effective strategy to increase the efficiency of radiotherapy. Butein (2', 3, 4, 4'-Tetrahydroxychalcone), a polyphenolic compound of flavonoids family, presents anti-cancer properties and inhibits the signaling pathways associated with radiation resistance. Therefore, we hypothesized that butein in combination with radiation may increase radiosensitivity. To evaluate the radiosensitizing effect of butein, we used MKN-45 cell line and performed several assays such as MTT, soft-agar colony formation, apoptosis, cell cycle, and comet assays. Based on obtained results, butein significantly enhanced radiosensitivity of MKN-45 cells. Butein treatment abrogated the radiation-induced G2/M cell cycle arrest, increased DNA damage, enhanced apoptosis, and reduced colony-forming ability of irradiated cells. This study on MKN-45 cells demonstrates that combination of butein with radiotherapy increases its radiosensitivity by abrogating the radiation-induced G2/M blockage, impairing DNA repair, and enhancing apoptotic and reproductive cell death. Therefore, we suggest butein as a candidate for combination with radiation therapy to decrease dose of radiation delivered to the patients and its corresponding side effects.

Identifiants

pubmed: 34271434
pii: S0006-291X(21)01059-7
doi: 10.1016/j.bbrc.2021.07.022
pii:
doi:

Substances chimiques

Chalcones 0
butein 4WVS5M0LGF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-40

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report that they have no conflict of interest.

Auteurs

Zahra Habibi-Kelishomi (Z)

Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. Electronic address: zhabibi@ut.ac.ir.

Bahram Goliaei (B)

Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. Electronic address: goliaei@ut.ac.ir.

Alireza Nikoofar (A)

Department of Radiotherapy, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: arnikoofar@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH